RCT Expands Its International Presence to the Far East
Tucson, AZ – Jul 09, 2002
Research Corporation Technologies has begun work with Japanese business development partners to promote RCT’s biotechnology licensing and venture investment programs in Japan and other Far Eastern countries.
RCT’s new BioJapan Ventures collaborators include Sosei Co. Ltd. in Tokyo, Primmune K.K. in Osaka and other skilled Japanese professionals.
The BioJapan Ventures partners will primarily identify and develop contacts with companies that could benefit from RCT’s Gene Expression Technologies (GET) licensing program. The GET program offers widely used gene expression systems and associated technologies at affordable costs. The program offers flexible, nonexclusive licenses with manageable fees and royalties dependent on fields of use. BioJapan Ventures will also work to identify new technologies from Japanese universities, research institutions, companies and technology licensing organizations suitable for inclusion in the GET program or RCT’s biomedical venture-development program.
“Our partners’ knowledge of companies, institutions and individuals in Japan, and of the Japanese language and culture will prove very useful in bringing our programs closer to interested Japanese companies and researchers,” said GET Director Bennett N. Cohen.
Founded in 1990, Sosei has carried out virtual biomedical technology development programs, and has successfully assisted vast numbers of pharmaceutical and biotech companies in commercial ventures that bridge Japan and the West over the past 10 years.
Primmune K.K. (Prime + Immune), founded in 2000, has been conducting cancer gene therapy and immunotherapy, collaborating with academics in research and development programs, and consulting for European biotechnology companies developing business in the Far East.
For additional information, contact Bennett N. Cohen, Ph.D., RCT Managing Director, (520) 748-4400, (520) 748-0025 fax.